STRO — Sutro Biopharma

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Sutro Biopharma

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$25.57
Market Cap$516M
Float10.5M
Shares Outstanding16.6M
P/E (Forward)10.03
Price/Sales (TTM)5.18
vs. Analyst Target+82.0% to analyst PT
Profit Margin-154.21%
Operating Margin (TTM)-203.91%
Revenue (TTM)$99.6M
Dividend RateNone
Analyst Target Price$46.55 (10 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $42.7M -$32.1M -$34.2M -$23.8M
2021 $61.9M -$106M $52.1M -$97.6M
2022 $67.8M -$119M $59.5M -$105M
2023 $154M -$107M $147M -$67.9M
2024 $62.0M -$227M $54.8M -$180M
2025 $102M -$191M $95.2M -$97.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $63.7M -$11.5M
Sep 2025 $9.7M -$56.9M
Dec 2025 $11.6M -$46.8M
Mar 2026 $14.5M -$38.5M

Ownership & Float

Insider Ownership2.3%
Institutional Ownership86.5%
Short Float9.3%
% of All Funds Holding0.80%
Number of Funds Holding66

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$30.00Near-term / short-term trend
Weekly40-Week SMA$16.60Medium-term trend
Weekly80-Week SMA$15.00Cyclical trend (business cycle)
Weekly200-Week SMA$34.78Secular trend (multi-year)
Monthly10-Month SMA$17.18Near-term monthly trend
Monthly20-Month SMA$16.27Medium-term monthly trend
Monthly40-Month SMA$29.00Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$25.20 support 2.11x 0 months ago
$36.70 resistance 1.68x 0 months ago
$19.90 support 1.94x 1 months ago
$14.80 support 1.18x 2 months ago
$11.50 support 1.07x 3 months ago

Historical Earnings Reactions (31 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 1.03% 0.11% 54.84% 14.13% -20.00%
1 Day 1.39% 2.28% 64.52% 16.32% -35.20%
1 Week 2.02% 1.39% 54.84% 64.78% -38.40%
2 Weeks 2.16% -1.22% 46.67% 64.78% -40.80%
1 Month 7.00% 4.28% 53.33% 92.27% -53.60%

Next earnings: August 2, 2026 (68 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan1.1%62.5%8
Feb-3.4%37.5%8
Mar-1.4%62.5%8
Apr1.0%25.0%8
May-0.8%57.1%7
Jun-7.4%28.6%7
Jul7.0%57.1%7
Aug7.5%71.4%7
Sep-7.4%42.9%7
Oct7.3%62.5%8
Nov-2.8%37.5%8
Dec8.3%50.0%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.06% 50.1% 361
Tuesday -0.05% 44.1% 395
Wednesday 0.15% 45.9% 392
Thursday 0.15% 46.9% 384
Friday 0.01% 47.7% 386

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 86.5%

Insider Transactions — Smart Summary

Total insider ownership: 2.3%

Founder-led management: James Swartz (Founder)

12-Month Insider Activity Summary

Total Filings5
Net Value+$49,608.747
Net Shares Change111,754
% of Float1.1%
C-Suite Filings4
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
MATSUI CONNIE +$39,950 1 1 buy
Chow Gregory K. CFO +$15,997.5 1 1 buy
Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER +$13,606.8 1 1 buy
Chung Jane Chief Executive Officer +$10,011.25 1 1 buy
Pauling David Chief Admin. Ofcr. and GC +$9,993.197 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-10-16 – 2025-10-16 5 5 +$89,558.747 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-10-16 Pauling David Chief Admin. Ofcr. and GC +$9,993.197 Transaction at $0.80, now +3099.4%
2025-10-16 Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER +$13,606.8 Transaction at $0.80, now +3094.7%
2025-10-16 Chung Jane Chief Executive Officer +$10,011.25 Transaction at $0.80, now +3092.7%
2025-10-16 Chow Gregory K. CFO +$15,997.5 Transaction at $0.81, now +3056.8%
2025-10-16 MATSUI CONNIE +$39,950 Transaction at $0.80, now +3100.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Sutro Biopharma (STRO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for STRO on Trend Edge →